LM-168

The primary objectives of the Phase I dose-escalation phase are to evaluate the safety and tolerability of LM-168, either alone or in combination with toripalimab, in patients with advanced solid tumors, determine the maximum tolerated dose (MTD), and explore the recommended Phase II dose (RP2D). The pharmacokinetic (PK) properties and immunogenicity of LM-168 will also be evaluated, as will the preliminary anti-tumor activity of LM-168, either alone or in combination with toripalimab, in patients with advanced solid tumors. The primary objectives of the Phase II dose-expansion phase are to evaluate the preliminary anti-tumor activity of LM-168, either alone or in combination with toripalimab, in patients with advanced solid tumors, as well as the safety and tolerability of LM-168, either alone or in combination with toripalimab, and to assess the pharmacokinetic (PK) properties and immunogenicity of LM-168.